Гипертрофия левого желудочка и ренин-ангиотензин-альдостероновая система: в фокусе блокаторы АТ1-ангиотензиновых рецепторов

1. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control between developing and developed countries. J Hypertens 2009; 27 (5): 963–75.
2. Шальнова С.А. Эпидемиология артериальной гипертензии в России: портрет больного. Артериальная гипертензия (Клінічний семінар). 2008; 2 (2).
3. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27 (11): 2121–58.
4. Шляхто E.В., Конради А.О., Захаров Д.В., Рудоманов О.Г. Структурно-функциональные изменения миокарда у больных гипертонической болезнью. Кардиология. 1999 (2): 49–55.
5. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment. A meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084–91.
6. Rosei EA et al. Hypertensive heart disease: diagnostic and therapeutic guidelines Commissione congiunta Società Italiana dell'lpertensione Arteriosa; Società Italiana di Cardiologia. Associazione Nazionale Medici Cardiologi Ospedalieri. G Ital Cardiol 2008; 9 (6): 427–54.
7. Artham SM. Clinical impact of left ventricular hypertrophy and implications for regression Prog. Cardiovasc Dis 2009; 52 (2): 153–67.
8. Budoff MJ, Ahmadi N, Sarraf G et al. Determination of left ventricular mass on cardiac computed tomographic angiography. Acad Radiol 2009; 16 (6): 726–32.
9. Барсуков А.В., Багаева З.В., Пронина Е.В. и др. Гипертрофия левого желудочка при эссенциальной гипертензии: актуальные вопросы патогенеза, диагностики и лечения. Артериальная гипертензия. 2009; 15 (4): 436–9.
10. Свеклина Т.С. Комплексная клинико-анамнестическая, лабораторно-инструментальная и прогностическая оценка больных артериальной гипертензией в сочетании с сахарным диабетом типа 2 и фибрилляцией предсердий. Автореф. дис. … канд. мед. наук. СПб., 2011; 24.
11. Barsukov A, Shoustov S, Resvantzev M, Pronina E. Asymmetrical left ventricle hypertrophy in essential hypertension: echocardiographic data. J Hypertens 2007; 25 (Suppl. 2): 99.
12. Конради А.О. Лечение артериальной гипертензии в особых группах больных. Гипертрофия левого желудочка. Артериальная гипертензия. 2005; 11 (2): 105–9.
13. Preis SR et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009; 120 (3): 212–20.
14. Lieb W et al. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study. Circulation 2009; 119 (24): 3085–92.
15. Tsioufis C et al. Left ventricular hypertrophy vs chronic kidney disease as predictors of cardiovascular events in hypertension: a Greek 6-year follow-up study. Original papers. Epidemiol 2009; 27 (4): 744–52.
16. Devereux RB, Vakili BA, Okin PM. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141 (3): 334–41.
17. Verdecchia P et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97 (1): 345–52.
18. Verdecchia P et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 3 (7): 1829–35.
19. Gueyffier F et al. Identification of risk factors in hypertensive patients. Circulation 1999; 100 (18): 88–94.
20. Casale PN et al. Value of echocardiographic measurements of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173–8.
21. Verdecchia P et al. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. J Heart 2004; 5 (7): 505–10.
22. Haywood LJ et al. ALLHAT Collaborative Research Group Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and ipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 2009; 54 (22): 2023–31.
23. Kannel WB et al. Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004; 148 (1): 16–26.
24. Schnabel RB et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 2009; 373 (9665): 739–45.
25. Барсуков А.В., Глуховской Д.В. Некоторые клинико-анамнестические особенности пациентов с артериальной гипертензией в зависимости от объема левого предсердия. Вестн. РВМА. 2011; 2: 41.
26. Krumholz HM, Larson M, Levy D. Prognosis of left vernacular geometric patterns in Framingham Heart Study. J Am Coll Cardiol 1995; 25: 884–97.
27. Ghali J, Kadakia S, Cooper R et al. Impact of left ventricular hypertrophy patterns on ventricular arrhythmias in the absence of coronary artery disease. J Am Coll Cardiol 1991; 17: 1277–82.
28. Барсуков А.В., Зобнина М.П., Багаева З.В. и др. Ретроспективная оценка выживаемости пациентов с артериальной гипертензией в сочетании с концентрической или эксцентрической гипертрофией левого желудочка. Материалы III Всероссийской научно-практической конференции c международным участием «Некоронарогенные заболевания сердца: диагностика, лечение, профилактика». СПб., 2011; 20.
29. Kohara K. Relation of left ventricular hypertrophy and geometry to asymptomatic cerebrovascular damage in essential hypertension. Am J Cardiol 1999; 17: 1277–82.
30. Кушаковский М.С. Гипертоническая болезнь (эссенциальная гипертензия). СПб.: СОТИС, 1995; с. 311.
31. Jansen PM, Danser AH, Imholz BP et al. Aldosterone-receptor antagonism in hypertension. J Hypertens 2009; 27 (4): 680–9.
32. Muller-Brunotte R et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan left ventricular hypertrophy investigation versus Atenolol (SILVHIA). J Hypertens 2007; 25: 1958–66.
33. Шустов С.Б., Баранов В.Л., Кадин Д.В. Состояние сердечной мышцы у больных, прооперированных по поводу синдрома Кона. Вестн. ВМА. 2000; 1: 40–4.
34. Барсуков А.В., Багаева З.В., Кадин Д.В. и др. Минералокортикоидный эксцесс и гипертрофия левого желудочка. Артериальная гипертензия. 2008; 14 (3): 211–9.
35. Carey RM. Primary aldosteronism. Horm Res 2009; 7 (Suppl. 1): 8–12.
36. Navarro-Lopez F et al. Left ventricular hypertrophy in asymptomatic essential hypertension: its relationship with aldosterone and the increase in sodium-proton exchanger activity. Eur Heart J 1993; 14 (Suppl. 1): 38–41. 
37. Ruilope LM. Aldosterone, hypertension, and cardiovascular disease. Hypertension 2008; 52: 207–8.
38. Барсуков А.В. Состояние сердечно-сосудистой и нейрогуморальной регуляторной систем у лиц молодого возраста с артериальной гипертензией с различной степенью стабильности гипертензионного синдрома. Автореф. дис. … д-ра мед. наук. СПб., 2001; 48.
39. Le Winter M et al. Heart failure with normal systolic function. Online Coverage from the American College of Cardiology 48 Annual Scientific Session 1999.
40. Евдокимова А.Г. Особенности применения эналаприла (Берлиприл®) у больных с артериальной гипертонией. Трудный пациент. 2008; 10: 4–10.
41. Dostal DE. The cardiac renin-angiotensin system: novel signaling mechanisms related to cardiac growth and function. Regul Pept 2000; 91: 1–11.
42. Leri A, Liu Y, Claudio PP, Kajstura J et al. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 1999; 154 (2): 567–80.
43. Zhang DY, Morgan TO. Effects of aortic ligation on the renin angiotensin system in hydronephrotic mice. Blood Press 1999; 8 (2): 122–8.
44. Malhotra R, Sadoshima J, Brousius FC. Mechanical stretch and angiotensin II differentially upregulate the renin-angiotensin system in cardiac myocytes in vitro. Circ Res 1999; 85: 137–46.
45. Verdecchia P. Controlling blood pressure in patients with left ventricular hypertrophy. Renin Angiotens System Cardiovascular Med 2006; 2 (3): 2–5.
46. Xi GL, Cheng JW, Lu GC. Meta-analysis of randomized control trials comparing telmisartan with losartan in the treatment of patients with hypertension. Am J Cardiol 2008; 21: 546–52.
47. Murasawa S, Matsubara H, Mori Y. Angiotensin II initiates tyrosine kinase Pyk2-dependent signalings leading to activation of Rac1-mediated c-Jun NH2-terminal kinase. J Biol Chem 2000; 275: 26 856–63.
48. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II–induced cardiomyocyte hypertrophy. Hypertension 1996; 28: 635–40.
49. Wharton J, Morgan K, Rutherford RA et al. Differential distribution of angiotensin AT2-receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998; 284: 323–8.
50. Yasunari K, Yasunari K, Maeda K et al. Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovascular & Hematological Agents 2005; 3: 61–7.
51. Young M et al. Mineral corticoids, hypertension and cardiac fibrosis. J Clin Invest 1994; 93: 2578–83.
52. Brunner HR, Gavras H, Mimran A et al. Eprosartan Monograph. London 2000; 250.
53. Grassi G. Renin-angiotensin-sympathetic cross-talks in hypertension: reappraising the relevance of peripheral interactions. J Hypertens 2001; 19: 1713–6.
54. Devereux RB et al. Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996; 14 (Suppl.): 95–101.
55. Schmieder RE. Hypertension and diabetes: what are the pros to treating early surrogates? Diabet Care 2009; 32 (Suppl. 2): 294–7.
56. Sheridan DJ. Regression of left ventricular hypertrophy: do antihypertensive classes differ? J Hypertens 2000; 18 (3): 21–7.
57. Horký K et al. Reducing food salt content – a neglected approach to hypertension prevention and treatment in the population. Vnitr Lek 2009; 55 (9): 797–801.
58. Muisan M et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091–105.
59. Yasunari K, Maeda K, Nakamura M. Pressure promotes angiotensin II-mediated migration of human coronary smooth muscle cells through increase in oxidative stress. Hypertension 2002; 39: 433–7.
60. Wong PC, Hart SD, Zaspel AM et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands J Pharmacol Exp Ther 1990; 255: 584–92.
61. Gohlke P, Linz W, Scholkens BA et al. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension 1996; 28: 397–402.
62. Wong WT, Tian XY, Xu A et al. Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 2010; 13: 757–68.
63. Bohm M, Lippoldt A, Wienen W et al. Reduction of cardiac hypertrophy in TGR (mREN) 27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163–164: 217–21.
64. Klingbeil AU et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115 (1): 41–6.
65. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment. A meta-analysis of randomized comparative studies. Hypertension 2009; 54: 1084–91.
66. Mancia G, Parati G, Omboni S et al. Ambulatory blood pressure monitoring. Clin Exp Hypertens 1999; 21: 703–15.
67. Wienen W, Richard S, Champeroux P, Audeval-Gerard C. Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. JRAAS 2001; 2: 31–6.
68. Lijnen PJ, Petrov VV, Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. JRAAS 2001; 2: 117–22.
69. Schumacher H, Mancia G. The safety profile of telmisartan as monotherapy or combined with hydrochlorothiazide: a retrospective analysis of 50 studies. Blood Press 2008; 1 (Suppl.): 32–40.
70. Friedrich MG, Dahlöf B, Sechtem U et al. TELMAR Investigators of telmisartan with metoprolol over a period of six months rationale and study design imaging in patients with mild-to-moderate hypertension a prospective, randomised, double-blind comparison. J Renin-Angiotensin-Aldosterone Syst 2003; 4: 234–43.
71. Cowan BR, Young AA, Anderson C et al. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial – ONTARGET). Am J Cardiol 2009; 104 (11): 1484–9.
72. Yusuf S. and TRANSCEND investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372 (9644): 1174–83.
73. Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008; 358 (15): 1547–59.

А.В.Барсуков*1, Д.В.Глуховской1, М.С.Таланцева1, З.В.Багаева2, Е.В.Пронина3, М.П.Зобнина1, Т.С.Свеклина1, А.Е.Коровин1

1 ФГКВОУ ВПО Военная медицинская академия им. С.М.Кирова Минобороны РФ, Санкт-Петербург;
2 ГБУЗ «Госпиталь ветеранов войн», Москва;
3 Санкт-Петербургский филиал ФГБМУ «Медицинский центр при Спецстрое России»
*avbarsukov@yandex.ru

________________________________________________

A.V.Barsukov*, D.V.Glukhovskoy, M.S.Talantseva, Z.V.Bagaeva, E.V.Pronina, M.P.Zobnina, T.S.Sveklina, A.E.Korovin
*avbarsukov@yandex.ru